GlassScriptPhysician profile
Kevin Campbell
NPI 1700820776
$10,501.76
in general payments reported to CMS, 2019-2025
31 companies · $4,092 in 2025
The $4,092 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,103 · 2020: $664 · 2021: $757 · 2022: $952 · 2023: $543 · 2024: $1,391 · 2025: $4,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,539 · Food and Beverage: $1,487 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,539.38 |
| Food and Beverage | $1,486.76 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,663.26 | 2025 | |
| Coloplast Corp | $2,384.96 | 2019-2024 | Speedicath |
| Verity Pharmaceuticals INC. | $1,000.00 | 2024 | Tlando |
| Boston Scientific Corporation | $711.60 | 2019-2024 | Ams 700 |
| Janssen Biotech, INC. | $473.54 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $377.67 | 2019-2023 | Myrbetriq |
| Urogen Pharma, INC. | $305.39 | 2021-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $200.01 | 2022 | |
| Axonics, INC. | $168.29 | 2020-2024 | Axonics |
| Abbvie INC. | $160.74 | 2019-2024 | |
| Acerus Pharmaceuticals Corporation | $134.25 | 2021 | |
| Dendreon Pharmaceuticals LLC | $128.36 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $112.45 | 2023-2025 | |
| Olympus America INC. | $111.38 | 2023-2025 | Itind System |
| Tolmar Pharmaceuticals, INC. | $109.53 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $67.05 | 2025 | |
| Merck Sharp & Dohme LLC | $62.60 | 2021-2025 | Keytruda |
| Sumitomo Pharma America, INC. | $48.31 | 2023-2025 | Gemtesa, Orgovyx |
| Karl Storz Endoscopy-America | $30.99 | 2024-2025 | |
| Urovant Sciences INC | $28.24 | 2022 | |
| Foundation Medicine, INC. | $26.16 | 2020-2021 | |
| Pfizer INC. | $25.58 | 2019-2022 | |
| Teleflex LLC | $24.89 | 2023 | Urolift |
| Clinigen, INC. | $24.52 | 2019 | |
| Endo USA, INC. | $23.28 | 2025 | Aveed, Xiaflex |
| Sun Pharmaceutical Industries INC. | $22.03 | 2023 | Yonsa |
| Accord Healthcare, INC. | $20.21 | 2023 | |
| Myovant Sciences INC. | $18.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.87 | 2022 | |
| Progenics Pharmaceuticals, INC. | $12.69 | 2023 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.